West Pharmaceutical Services, Inc. Aktie News

EXTON, Pa. , Oct. 27, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the launch of its West Synchrony™ Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany. This innovative system marks a significant shift in drug delivery solutions by offering a fully verified p...

EXTON, Pa. , Oct. 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences:  UBS Global Healthcare Conference: Fireside chat at 9:30 AM ET on Tuesday, November 11, 2025, in Palm Beach Gardens, FL. Jefferies Global Healthc...

It was a beat-and-raise third quarter for the healthcare services specialist. It experienced broad growth throughout its product and service offerings.

West Pharmaceutical Services, Inc. (NYSE:WST ) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants John Sweeney - Head of Investor Relations Eric Green - Non-Independent Chair of the Board, President & CEO Robert McMahon - Senior VP & CFO Conference Call Participants Paul Knight - KeyBanc Capital Markets Inc., Research Division Michael Ryskin - BofA Securities, Research Divi...

Medical equipment maker West Pharmaceutical raised its annual profit forecast on Thursday, after posting better-than-expected results for the third quarter, banking on strong demand for its components used in GLP-1 weight-loss and diabetes drugs.

- Delivered solid growth across Proprietary Products and Contract Manufacturing Segments -  - Achieved double-digit growth in HVP Components - - Strengthened executive leadership team, including recently appointed CFO Robert McMahon - - Increases Full-Year 2025 Revenue and EPS Guidance - EXTON, Pa. , Oct. 23, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provide...

West Pharmaceutical Services earns a Buy rating with a $320 price target, reflecting ~18% upside with strong long-term growth prospects. WST's high-value product mix is expanding, driving margin growth through proprietary, high-margin offerings and regulatory stickiness. Surging demand for GLP-1 therapies and biologics underpins durable growth for WST's containment and delivery systems, reinfor...

EXTON, Pa. , Oct. 9, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 23, 2025, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Easter...